Observational Study of the Use of Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting in Austria, Germany and Switzerland
Observational Study of the Use of Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting in Austria, Germany and Switzerland
An observational study to assess the effectiveness, health economic-relevant costs and participant reported outcomes in participants with Chronic lymphocytic leukemia (CLL) receiving venetoclax as a monotherapy or in combination with rituximab, obinutuzumab, ibrutinib, or acalabrutinib as prescribed at the discretion of the physician and in accordance with local clinical practice and label.
Inclusion Criteria:
- Participant with chronic lymphocytic leukemia (CLL) who start venetoclax therapy can be included in the study if treated as specified in the local label for any specific line of treatment.
Exclusion Criteria:
- None
johannes.huelsenbeck@abbvie.com+49 611-1720-3036
stefan.lorenz@abbvie.com
Salzburg, 5020, Austria
Villingen-Schwenningen, Baden-Wurttemberg 78052, Germany
Augsburg, Bavaria 86150, Germany
Bremerhaven, Free Hanseatic City of Bremen 27576, Germany
Frankfurt am Main, Hesse 60389, Germany
Westerstede, Lower Saxony 26655, Germany
Regensburg, State of Berlin 93053, Germany
Freiburg im Breisgau, 79110, Germany
Neuchâtel, Canton of Neuchâtel 2000, Switzerland
Bellinzona, Canton Ticino 6500, Switzerland